Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial

详细信息    查看全文

• 作者：Masakazu Abe ; Yasuyuki Hirashima ; Yuka Kasamatsu…
• 关键词：Olanzapine ; Chemotherapy ; induced nausea and vomiting ; Cisplatin ; Highly ; emetogenic chemotherapy ; Antiemetic therapy
• 刊名：Supportive Care in Cancer
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：24
• 期：2
• 页码：675-682
• 全文大小：282 KB
• 参考文献：1.Bloechl-Daum B, Deuson RR, Mavros P, et al. (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. Clin Oncol 24:4472–4478CrossRef
  2.MASCC/ESMO Antiemetic Guideline 2013. http://​www.​mascc.​org/​assets/​documents/​mascc_​guidelines_​english_​2013.​pdf Accessed 20 Mar. 2015.
  3.Basch E, Prestrud AA, Hesketh PJ, et al. (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198PubMed CrossRef
  4.National Comprehensive Cancer Network (2014) NCCN clinical practice guidelines in oncology: antiemesis, Version 1. http://www.​nccn.​org/​professionals/​physician_​gls/​pdf/​antiemesis.​pdf Accessed 20 Mar. 2015.
  5.Japan Society of Clinical Oncology (2014) Guidelines for the proper use of antiemetics, version 1.2. Kanehara, Tokyo.
  6.Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098PubMed CrossRef
  7.Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000–1006PubMed CrossRef
  8.Campos D, Pereira JR, Reinhardt RR, et al. (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759–1767PubMed
  9.Hesketh PJ, Grunberg SM, Gralla RJ, et al. (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119PubMed CrossRef
  10.Takahashi T, Hoshi E, Takagi M, et al. (2011) Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 11:2455–2461
  11.Saito M, Aogi K, Sekine I, et al. (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115–124PubMed CrossRef
  12.Longo F, Mansueto G, Lapadula V, et al. (2011) Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 19:1159–1164PubMed CrossRef
  13.Tamura K, Aiba K, Saeki T, et al. (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 2015 Feb. 15.
  14.Takeshima N, Matoda M, Abe M, et al. (2014) Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial. Support Care Cancer 22:2891–2898PubMed CrossRef
  15.Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188–195PubMed CrossRef
  16.Tan L, Liu J, Liu X, et al. (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131–137PubMed PubMedCentral CrossRef
  17.Liu J, Tan L, Zhang H, et al. (2014) QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. Eur J Cancer Care 2014 Nov. 18.
  18.Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663PubMed CrossRef
  19.Abe M, Komeda S, Kuji S, et al. (2013) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting resistant to standard antiemetic treatment for highly emetogenic chemotherapy. Palliat Care Res 8:127–134CrossRef
  20.Abe M, Kasamatsu Y, Kado N, et al. (2015) Efficacy of olanzapine combined therapy for patients receiving highly emetogenic chemotherapy resistant to standard antiemetic therapy. Biomed Res Int (in Press).
  21.Italian Group for Antiemetic Research (2000) Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Support Care Cancer 8:229–232CrossRef
  22.Roscoe JA, Morrow GR, Aapro MS, et al. (2011) Anticipatory nausea and vomiting. Support Care Cancer 19:1533–1538PubMed PubMedCentral CrossRef
  23.Morrow GR, Roscoe JA, Hickok JT, et al. (1998) Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park) 12:32–37
  24.Passik SD, Navari RM, Jung SH, et al. (2004) A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Investig 22:383–388CrossRef
  25.Navari RM, Einhorn LH, Passik SD, et al. (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 13:529–534PubMed CrossRef
  26.Navari RM, Einhorn LH, Loehrer PJ Sr., et al. (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 15:1285–1291.PubMed CrossRef
  27.Bymaster F, Perry KW, Nelson DL, et al. (1999) Olanzapine: a basic science update. Br J Psychiatry 37:36–40
  28.Passik SD, Lundberg J, Kirsh KL, et al. (2002) A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag 23:526–532CrossRef
  29.Kast RE, Foley KF (2007) Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care 16:351–354CrossRef
  30.Kaneishi K, Kawabata M, Morita T (2012) Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manag 44:604–607CrossRef
  31.Navari RM, Brenner MC (2010) Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer 18:951–956PubMed CrossRef
  32.Pleuvry BJ (2003) Physiology and pharmacology of nausea and vomiting. Anaesth Intensive Care 4:349–352CrossRef
  33.Arakawa R, Okumura M, Ito H, et al. (2010) Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry 71:1131–1137PubMed CrossRef
  
• 作者单位：Masakazu Abe (1)
  Yasuyuki Hirashima (1)
  Yuka Kasamatsu (1)
  Nobuhiro Kado (1)
  Satomi Komeda (1)
  Shiho Kuji (1)
  Aki Tanaka (1)
  Nobutaka Takahashi (1)
  Munetaka Takekuma (1)
  Hanako Hihara (2)
  Yoshikazu Ichikawa (2)
  Yui Itonaga (3)
  Tomoko Hirakawa (3)
  Kaei Nasu (3)
  Kanoko Miyagi (4)
  Junko Murakami (4)
  Kimihiko Ito (4)
  
  1. Department of Gynecology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan
  2. Department of Obstetrics and Gynecology, Japanese Red Cross Shizuoka Hospital, 8-2 Outemachi, Aoi-Ward, Shizuoka City, Shizuoka, 420-0853, Japan
  3. Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasamamachi, Yufu City, Oita, 879-5593, Japan
  4. Department of Obstetrics and Gynecology, Kansai Rousai Hospital, 3-1-69 Inabaso, Amagasaki-City, Hyogo, 660-8511, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Nursing
  Nursing Management and Research
  Pain Medicine
  Rehabilitation Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-7339

文摘

Purpose Olanzapine is effective in chemotherapy-induced nausea and vomiting (CINV). In patients receiving highly emetogenic chemotherapy (HEC), its efficacy was reported as rescue therapy for breakthrough emesis refractory to triplet therapy (palonosetron, aprepitant, and dexamethasone). However, its preventive effects with triplet therapy for CINV are unknown. This study aimed to investigate efficacy and safety of preventive use of olanzapine with triplet therapy for CINV of HEC.